$$ Advanced Cell Technology $$
eins kann ich dir aber sagen:STEIG IMMER IN EINER AKTIE EIN ;WO NOCH WENIG INTERESSE IST.
falls du von dieser firma überzeugt bist das sie potenzial hat.
es ist dir überlassen,es ist dein geld und es wird dein gewinn o. verlust werden.
gruß sky7
” We are pleased that shareholders have elected to approve each of the proposals in the proxy, supporting the Company's efforts to further develop its stem cell technology platform,” said William M. Caldwell IV, the Company's Chairman and Chief Executive Officer. "Wir freuen uns, dass die Aktionäre gewählt haben, zu jedem der Vorschläge in den Proxy zu genehmigen, die Unterstützung der Anstrengungen des Unternehmens um eine Weiterentwicklung ihrer Stammzell-Technologie-Plattform", sagte William M. Caldwell IV, des Unternehmens, Chairman und Chief Executive Officer. ”We remain focused on submitting an IND for the RPE program to the FDA for approval to commence a Phase I Clinical Trial prior to the end of the year.” "Wir bleiben auf der Einreichung eines IND für die RPE-Programm der FDA für die Zulassung zu einer Phase-I-Studie beginnen vor dem Ende des Jahres konzentrieren."
The Company is in the process of filing the requisite documents with the appropriate regulatory agencies to enact the amendments. Die Gesellschaft wird in den Prozess der Einreichung der erforderlichen Unterlagen mit den zuständigen Aufsichtsbehörden, um die Änderungen zu erlassen.
Na wird doch mal langsam wieder Zeit für die nächstw Gewinn und Kursanstiegswelle, wenn ich so die letzten paar Monate betrachte...
ich selber bin investiert miit mehreren tausend stück
mfg
Der Aufstieg, so gering er auch sein mag, hat Geld gekostet. Die Anforderungen in diesem Index sind ebenfalls andere, bzw. höhere: So wird von Aktien, die in diesem Index gehandelt werden, regelmäßig der Quartalsbericht verlangt.
Bitte mich nicht auf diese Infos festzunageln. Vielleicht wissen andere mehr.
könnte bei erfolg nen leckeren anstieg bedeuten
werd owhl heute nochmal nachlegen, wenn das ding irgendwann zündet gehts durch die decke ;)
Awaiting IND Targetting a Twenty-Eight Billion Dollar Market (OTC:ACTC.OB)WEBWIRE – Monday, November 02, 2009
Contact InformationMichael Vlaicu
President & CEO
MiV Investments Inc.
4163126929
michaelvlaicu@stockshaven.comMiV Investments Inc. has initiated independent research coverage on Advanced Cell Technology Inc. (OTC:ACTC.OB), which is anticipating a filing of an investigational new drug (IND) application which takes on a 28B Age-related macular degeneration (AMD) market, with over 30 million people affected by the disease. The company expects to file the IND prior to the end of Q409.
Macular degeneration is a medical condition usually of older adults that results in a loss of vision in the center of the visual field (the macula) because of damage to the retina. It occurs in “dry” and “wet” forms. It is a major cause of visual impairment in the elderly ( greater than 50 years).
Macular degeneration can make it difficult or impossible to read or recognize faces, although enough peripheral vision remains to allow other activities of daily life. There is no other existing therapeutic treatments which regenerate the lost cells, leaving 90% of Age-related macular degeneration (AMD) patients with dry variety as an unmet need. This condition affects more than 15% of elders aged 75 and above, leaving it as one of the top threats to an elder’s health.
The company has also taken major strides, recently moving from the PINK sheets, to the OTC bulletin and sufficing the qualifications needed to be pink sheets compliant. Technicals on the company’s stock have also been highly bullish as of late, sitting at a nine month price low, all the while anticipating news on what could be the beginning of a revolutionary new drug.
The company is in preparation of its first IND filing with the Food and Drug Administration for its retinal pigment epithelium (RPE) cell program for the treatment of various eye diseases. The Company noted that in the next few weeks, it will be completing the preclinical work necessary for filing the IND.
To date, no adverse events have occurred in testing. The results will be part of the submission which Advanced Cell expects to submit to the FDA prior to the end of the year. “We are very pleased with the long-term safety and efficacy data,” said Dr. Robert Lanza, ACT’s Chief Scientific Officer. “We have carried out pre-clinical studies using these cells in multiple animal models, and to-date have not seen any teratoma formation or untoward pathological reactions. We are optimistic that human embryonic stem cells (hESCs) will serve as a potentially safe and inexhaustible source of RPE for the treatment of a range of macular degenerative diseases.”
Existing therapies only treat the condition and do not regenerate cells of the macula that have been damaged. Plus, existing therapies only treat wet AMD, not dry AMD, leaving a significant unmet need for an effective treatment for the 90% of AMD patients who have the dry variety. The company expects to file an IND for its RPE program by end of 2009.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the field of regenerative medicine. The Company has acquired, developed and maintain a portfolio of patents and patent applications that form the base for its research and development efforts in the area of embryonic and adult stem cell research. The Company’s technology base, in combination with its know-how, provides an advantage and will facilitate the successful development and commercialization of products for use in treatment of an array of chronic degenerative diseases and in regenerative repair of acute disease, such as trauma, myocardial infarction and burns. The Company’s embryonic stem (ES) cell research programs are divided into three core categories: cellular reprogramming, reduced complexity program, and stem cell differentiation.
The full special report on the company appears today at http://www.stockshaven.com/...eight-billion-dollar-market-otcactc-ob/
Disclosure: Long ACTC
To feature a publicly traded company in StocksHaven.com Alerts or as a fully profiled company, email us at michaelvlaicu@stockshaven.com or visit http://www.stockshaven.com/ir_contract/ for more info
###
About MiV Investments Inc.
MiV Investments Inc. can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers Investor Relations contracting services.
For more financial and investment news, visit www.StocksHaven.com
Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as "expects" "anticipates" "plans" "believes" "scheduled" "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.
All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com on behalf of MiV Investments Inc. does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
Quelle: http://www.webwire.com/ViewPressRel.asp?aId=106848
was ist hier los? Hat jemand Infos?
Das ist echt nicht meine Woche...und die letzte Woche wars auch nicht...MIST!
ISIN US00752K1051
WKN A0F5H7
Ticker T2N
Name ADVANCED CELL TECH.DL-001
Land USA
Kategorie Aktien
Branche/Art Sonstige ausl. Aktien
Hauptindex
Börse Frankfurt
Zeit 04.11.2009, 09:12:24
Letzter Kurs (realtime) 0,006 EUR -90,00%
Volumen 0
Geld / Verkauf 0,060 EUR / 76.500
Brief / Kauf 0,085 EUR / 16.874
Seit Tagen schon wird hier dieser Kurs heftigst manipuliert, bzw. völlig abweichend vom US-Kurs eingestellt.
Wäre interessant zu wissen, welcher Makler in Frankfurt die Kurse einstellt. Vielleicht betrachtet der sein Gewerbe ja als eine Sparte der Freibeuterei.
Man könnte auch sein Geldinstitut beauftragen, sich an die Bafin zu wenden...
ich guck mal ob ich was finde!!
ND Filing for RPE Program Expected by 2009 Year-end; Company Announces Plans to File IND For Second Clinical Program During First Half of 2010
http://finance.yahoo.com/news/...logy-bw-2747460044.html?x=0&.v=1
vllt hofft da jemand auf panikverkäufe, aber ich hab meine ehh in amiland liegen!!
Form 8-K for ADVANCED CELL TECHNOLOGY, INC.
2-Nov-2009
Other Events
ITEM 8.01 Other Events.
The Company intends to sell (the "Offering") promissory notes in the principal amount of a minimum of $2,400,000, for a purchase price of a minimum of $2,000,000 (the "Notes"). The Notes will be convertible into shares of the Company's common stock at a conversion price of $0.10. Pursuant to the Offering, the Company also intends to issue (i) one-and-one third Class A warrants ("Class A Warrants") for each two shares of common stock underlying the Notes, to purchase shares of the Company's common stock with a term of five years and an exercise price equal to 110% of the closing price of the Company's common stock for the trading day preceding the initial closing date of the Offering (provided that, the initial exercise price shall not be less than $0.10), (ii) additional investment rights, exercisable until 9 months after the second closing date of the Offering ("Additional Investment Rights"), to purchase (a) promissory notes ("Air Notes") in the principal amount of a minimum of $2,400,000, for a purchase price of a minimum of $2,000,000, with a conversion price of $0.10, and one-and-one third Class A warrants ("Class A Warrants") for each two shares of common stock underlying the AIR Notes, to purchase shares of the Company's common stock with a term of five years and an exercise price equal to 110% of the closing price of the Company's common stock for the trading day preceding the initial closing date of the Offering (provided that, the initial exercise price shall not be less than $0.10).
The Company will be required to redeem the Notes monthly commencing in May 2009, in the amount of 14.28% of the initial principal amount of the Notes, in cash or common stock at the Company's option (subject to the conditions set forth in the Notes), until the Notes are paid in full..
The initial closing under the Offering will be for the purchase of a minimum of $1,200,000 principal amount of Notes, for a purchase price of a minimum of $1,000,000. The second closing under the Offering will be within 90 days of the initial closing under the Offering and will be for the purchase of a minimum of $1,200,000 principal amount of Notes, for a purchase price of a minimum of $1,000,000.
The disclosure in this current report on Form 8-K have been made pursuant to Rule 135 promulgated under the Securities Act of 1933, as amended (the "Act"). The securities offered pursuant to the Offering, have not been registered under the Act and are being sold in reliance upon an exemption from the registration requirements of the Act pursuant to Regulation D promulgated under the Act. Therefore, the securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Act and any applicable state securities laws. This current report on Form 8-K does not constitute an offer to sell any securities or a solicitation of an offer to purchase any securities.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
dann ist ja wieder alles in Ordnung...und ich dachte schon...
trotzdem könnte unser Baby auch mal starten :-)
If agreed by regulartory body the US Food and Drug Administration, the 12 patients with Stargardt’s disease included in the trial could become the first in the world to receive any kind of treatment based on embryonic stem cells.
Robert Lanza, of Advanced Cell Technology, which developed the therapy, said the application was an “important advance”.
He said: “After years of research and political debate, we’re finally on the verge of showing the potential clinical value of embryonic stem cells.”
http://www.birminghammail.net/...age-of-hope-to-teens-97319-25447711/